Sequential Treatment Strategy Using Fluoropyrimidine plus Bevacizumab Followed by Oxaliplatin for Metastatic Colorectal Cancer A Phase II Study (OGSG 1107)
2021
A phase II trial of ramucirumab plus irinotecan for patients with early relapced gastric cancer
The Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy (OGSG1201)
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy（OGSG1201）
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, RAS wild type colorectal cancer （OGSG 1602）
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory tofluoropyrimidine-and platinum-based chemotherapy (OGSG1201)
Randomized phase II study of DTX vs PTX in patients with ESCC refractory to 5-FU- and platinum-based chemotherapy（OGSG1201）
Randomized phase II study of CPT‑11 versus PTX versus each combination chemotherapy with S‑1 for advanced gastric cancer that is refractory to S‑1 or S‑1 plus CDDP: OGSG0701
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201